On September 12, 2022, the Single Distributor held an online meeting with Bayer representatives. The parties discussed issues of strategic partnership, development of the clinical trials market and transfer of advanced technologies in the healthcare sector.
The meeting was attended by Bayer's Head of Business Operations in the CIS and Russia Tilo Jorgal, Head of Radiology Business Operations in the CIS Irina Pankova, CEO of Bayer in Kazakhstan Lauma Valtere, Head of Legal Department Gulmira Baismakova, Medical Director Elena Gofman, Head of Market Access, Marketing and Sales Department Dulat Konakbayev and Market Access Manager Yerkhan Akhanbayev.
Welcoming remarks were made by the SK-Pharmacy LLP Chairman of the Board Yerkhat Iskaliyev and the head of business operations in the CIS countries and Russia Tilo Jorgal.
In turn, the Single Distributor informed the participants of the meeting about the centralized procurement system in Kazakhstan and the role of the Single Distributor in the drug supply system. Investment opportunities in the field of pharmaceuticals and cooperation initiatives with manufacturers of original drugs, raw materials for the production of medicines and medical devices were also announced.
The development of the production of expensive innovative products, the promotion of the industry in the direction of technology transfer, localization of original medicines and the production of substances is of key importance for the Kazakhstani pharmaceutical industry today.
In this regard, in order to implement the tasks set by the Head of State on the importance of cooperation with global corporations, attracting investors, ensuring the transfer of technologies and the latest developments, the Single Distributor takes the initiative to provide a platform for major brands to enter the country from packaging to the full production cycle.
Innovation plays an important role in overcoming the global challenges of humanity, Bayer, as a leader in the field of healthcare, provides innovative solutions designed to prevent and treat diseases.
The Single Distributor emphasized that a powerful incentive for the development of domestic production is the development of interaction with the major global pharmaceutical industry and the involvement of domestic research institutes, scientific laboratories of large medical universities like R&D centers, as well as their deployment in free economic and industrial zones.
The Kazakh side invited Bayer to develop contract manufacturing of medicines and medicinal raw materials, noting that this opens up broad prospects for development.
At the meeting, attention was paid to personnel issues in the healthcare industry. The parties noted that human resources determine the efficiency of health care systems, the quality and accessibility of medical care provided to the population. It is the highly qualified personnel in the country's healthcare system that make the industry efficient, affordable and improve the quality of medical care. Bayer expressed interest in discussing educational activities for the medical community in Kazakhstan.
Following the results of the online meeting, the participants expressed confidence that this meeting served as an opportunity for a constructive and open dialogue and will play an important role in the future implementation of the tasks set and also contributes to the further development of mutual cooperation.
Reference:
Bayer AG – German hemical-pharmaceutical transnational corporation founded in 1863. The headquarters is located in Leverkusen, North Rhine-Westphalia (Germany). One of the largest pharmaceutical companies in the world. The main regions of operation are the USA (30% of sales), Germany, China and Brazil.
Bayer AG was founded in Barmen (now part of Wuppertal, Germany) n 1863 by Friedrich Bayer and his partner, Johann Friedrich Weskott. The corporation's first significant pharmaceutical product was acetylsalicylic acid . In 1899, Aspirin became the registered trademark under which Bayer marketed acetylsalicylic acid worldwide.
.png)
.jpeg)